Global Fluralaner API 麻豆原创 Growth 2025-2031

Publication ID:

LPI04250267

Publication Date:

April 17, 2025

Pages:

105

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Fluralaner API market size is predicted to grow from US$ 82.2 million in 2025 to US$ 108 million in 2031; it is expected to grow at a CAGR of 4.7% from 2025 to 2031.
Fluralaner, isoxazoline class compound, is a systemic insecticide and acaricide with antiparasitic activity against cat and dog fleas and ticks. Fluralaner is an inhibitor of the arthropod nervous system. Fluralaner inhibits 纬-aminobutyric acid (GABA)-gated chloride channels (GABACls) and L-glutamate-gated chloride channels (GluCls). Potency of fluralaner is comparable to fipronil (a phenylpyrazole ectoparasiticide). Fluralaner API in this report.
Global key manufacturers of Fluralaner API include Nissan Chemical, Hikal, Hubei Masteam Bio-tech, Jiangsu Rivocean, Shaanxi Dideu, etc. Global top five manufacturers hold a share about 85%. Asia-Pacific is the largest market of Fluralaner API, holds a share over 35%. In terms of product, purity above 98% ones hold a larger segment, with a share over 75%. And in terms of application, the largest application is oral drug, with a share of over 70%.
The 鈥淔luralaner API Industry Forecast鈥� looks at past sales and reviews total world Fluralaner API sales in 2024, providing a comprehensive analysis by region and market sector of projected Fluralaner API sales for 2025 through 2031. With Fluralaner API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Fluralaner API industry.
This Insight Report provides a comprehensive analysis of the global Fluralaner API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Fluralaner API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Fluralaner API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fluralaner API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fluralaner API.
This report presents a comprehensive overview, market shares, and growth opportunities of Fluralaner API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Purity above 98%
Purity below 98%
Segmentation by Application:
Oral Drug
Topical Drug
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Nissan Chemical
Hikal
Hubei Masteam Bio-tech
Jiangsu Rivocean
Shaanxi Dideu
Zhejiang Gihi Chemicals
Hunan Huateng Pharmaceutical
Taizhou Crene Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Fluralaner API market?
What factors are driving Fluralaner API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Fluralaner API market opportunities vary by end market size?
How does Fluralaner API break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Fluralaner API Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Fluralaner API by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Fluralaner API by Country/Region, 2020, 2024 & 2031
2.2 Fluralaner API Segment by Type
2.2.1 Purity above 98%
2.2.2 Purity below 98%
2.3 Fluralaner API Sales by Type
2.3.1 Global Fluralaner API Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Fluralaner API Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Fluralaner API Sale Price by Type (2020-2025)
2.4 Fluralaner API Segment by Application
2.4.1 Oral Drug
2.4.2 Topical Drug
2.5 Fluralaner API Sales by Application
2.5.1 Global Fluralaner API Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Fluralaner API Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Fluralaner API Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Fluralaner API Breakdown Data by Company
3.1.1 Global Fluralaner API Annual Sales by Company (2020-2025)
3.1.2 Global Fluralaner API Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Fluralaner API Annual Revenue by Company (2020-2025)
3.2.1 Global Fluralaner API Revenue by Company (2020-2025)
3.2.2 Global Fluralaner API Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Fluralaner API Sale Price by Company
3.4 Key Manufacturers Fluralaner API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Fluralaner API Product Location Distribution
3.4.2 Players Fluralaner API Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Fluralaner API by Geographic Region
4.1 World Historic Fluralaner API 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Fluralaner API Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Fluralaner API Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Fluralaner API 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Fluralaner API Annual Sales by Country/Region (2020-2025)
4.2.2 Global Fluralaner API Annual Revenue by Country/Region (2020-2025)
4.3 Americas Fluralaner API Sales Growth
4.4 APAC Fluralaner API Sales Growth
4.5 Europe Fluralaner API Sales Growth
4.6 Middle East & Africa Fluralaner API Sales Growth
5 Americas
5.1 Americas Fluralaner API Sales by Country
5.1.1 Americas Fluralaner API Sales by Country (2020-2025)
5.1.2 Americas Fluralaner API Revenue by Country (2020-2025)
5.2 Americas Fluralaner API Sales by Type (2020-2025)
5.3 Americas Fluralaner API Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Fluralaner API Sales by Region
6.1.1 APAC Fluralaner API Sales by Region (2020-2025)
6.1.2 APAC Fluralaner API Revenue by Region (2020-2025)
6.2 APAC Fluralaner API Sales by Type (2020-2025)
6.3 APAC Fluralaner API Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Fluralaner API by Country
7.1.1 Europe Fluralaner API Sales by Country (2020-2025)
7.1.2 Europe Fluralaner API Revenue by Country (2020-2025)
7.2 Europe Fluralaner API Sales by Type (2020-2025)
7.3 Europe Fluralaner API Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Fluralaner API by Country
8.1.1 Middle East & Africa Fluralaner API Sales by Country (2020-2025)
8.1.2 Middle East & Africa Fluralaner API Revenue by Country (2020-2025)
8.2 Middle East & Africa Fluralaner API Sales by Type (2020-2025)
8.3 Middle East & Africa Fluralaner API Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Fluralaner API
10.3 Manufacturing Process Analysis of Fluralaner API
10.4 Industry Chain Structure of Fluralaner API
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Fluralaner API Distributors
11.3 Fluralaner API Customer
12 World Forecast Review for Fluralaner API by Geographic Region
12.1 Global Fluralaner API 麻豆原创 Size Forecast by Region
12.1.1 Global Fluralaner API Forecast by Region (2026-2031)
12.1.2 Global Fluralaner API Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Fluralaner API Forecast by Type (2026-2031)
12.7 Global Fluralaner API Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Nissan Chemical
13.1.1 Nissan Chemical Company Information
13.1.2 Nissan Chemical Fluralaner API Product Portfolios and Specifications
13.1.3 Nissan Chemical Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Nissan Chemical Main Business Overview
13.1.5 Nissan Chemical Latest Developments
13.2 Hikal
13.2.1 Hikal Company Information
13.2.2 Hikal Fluralaner API Product Portfolios and Specifications
13.2.3 Hikal Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Hikal Main Business Overview
13.2.5 Hikal Latest Developments
13.3 Hubei Masteam Bio-tech
13.3.1 Hubei Masteam Bio-tech Company Information
13.3.2 Hubei Masteam Bio-tech Fluralaner API Product Portfolios and Specifications
13.3.3 Hubei Masteam Bio-tech Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Hubei Masteam Bio-tech Main Business Overview
13.3.5 Hubei Masteam Bio-tech Latest Developments
13.4 Jiangsu Rivocean
13.4.1 Jiangsu Rivocean Company Information
13.4.2 Jiangsu Rivocean Fluralaner API Product Portfolios and Specifications
13.4.3 Jiangsu Rivocean Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Jiangsu Rivocean Main Business Overview
13.4.5 Jiangsu Rivocean Latest Developments
13.5 Shaanxi Dideu
13.5.1 Shaanxi Dideu Company Information
13.5.2 Shaanxi Dideu Fluralaner API Product Portfolios and Specifications
13.5.3 Shaanxi Dideu Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Shaanxi Dideu Main Business Overview
13.5.5 Shaanxi Dideu Latest Developments
13.6 Zhejiang Gihi Chemicals
13.6.1 Zhejiang Gihi Chemicals Company Information
13.6.2 Zhejiang Gihi Chemicals Fluralaner API Product Portfolios and Specifications
13.6.3 Zhejiang Gihi Chemicals Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Zhejiang Gihi Chemicals Main Business Overview
13.6.5 Zhejiang Gihi Chemicals Latest Developments
13.7 Hunan Huateng Pharmaceutical
13.7.1 Hunan Huateng Pharmaceutical Company Information
13.7.2 Hunan Huateng Pharmaceutical Fluralaner API Product Portfolios and Specifications
13.7.3 Hunan Huateng Pharmaceutical Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Hunan Huateng Pharmaceutical Main Business Overview
13.7.5 Hunan Huateng Pharmaceutical Latest Developments
13.8 Taizhou Crene Biotechnology
13.8.1 Taizhou Crene Biotechnology Company Information
13.8.2 Taizhou Crene Biotechnology Fluralaner API Product Portfolios and Specifications
13.8.3 Taizhou Crene Biotechnology Fluralaner API Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Taizhou Crene Biotechnology Main Business Overview
13.8.5 Taizhou Crene Biotechnology Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.